AZITRA INC

CEO Salva Francisco D. buys 4 + million Azitra shares and converts preferred stock, signaling confidence amid steep stock decline and upcoming clinical milestones.

Azitra Inc’s insider buying spree signals executive confidence in its dermatology‑engineered protein pipeline, but investors must watch clinical milestones and funding to validate the upside.

CEO buys Azitra Inc. convertible stock & warrants amid $31M private placement—insider confidence, potential upside vs. dilution risk.